By expenditures
| Name | Title | Type |
|---|---|---|
| Jeff Jones | Finance Director | Auditee |
| Eden Casareno | Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 350727 | 2024 | 2025-03-31 | Eadie & Payne LLP | $14.80M |
| 318408 | 2023 | 2024-09-03 | Eadie & Payne LLP | $18.00M |
| 305135 | 2022 | 2024-04-30 | Eadie & Payne LLP | $9.39M |
| 298952 | 2021 | 2024-03-27 | Eadie & Payne LLP | $1.29M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 350727 | 2024 | 2025-03-31 | 1118253 | 2024-002 | Significant Deficiency | Yes | L |
| 350727 | 2024 | 2025-03-31 | 1118252 | 2024-001 | Material Weakness | - | E |
| 350727 | 2024 | 2025-03-31 | 541811 | 2024-002 | Significant Deficiency | Yes | L |
| 350727 | 2024 | 2025-03-31 | 541810 | 2024-001 | Material Weakness | - | E |
| 318408 | 2023 | 2024-09-03 | 1062075 | 2023-007 | Significant Deficiency | Yes | A |
| 318408 | 2023 | 2024-09-03 | 1062074 | 2023-006 | Significant Deficiency | - | N |
| 318408 | 2023 | 2024-09-03 | 1062073 | 2023-005 | Significant Deficiency | Yes | L |
| 318408 | 2023 | 2024-09-03 | 1062072 | 2023-004 | Significant Deficiency | - | M |
| 318408 | 2023 | 2024-09-03 | 1062071 | 2023-003 | Significant Deficiency | Yes | I |
| 318408 | 2023 | 2024-09-03 | 1062070 | 2023-002 | - | Yes | L |
| 318408 | 2023 | 2024-09-03 | 485633 | 2023-007 | Significant Deficiency | Yes | A |
| 318408 | 2023 | 2024-09-03 | 485632 | 2023-006 | Significant Deficiency | - | N |
| 318408 | 2023 | 2024-09-03 | 485631 | 2023-005 | Significant Deficiency | Yes | L |
| 318408 | 2023 | 2024-09-03 | 485630 | 2023-004 | Significant Deficiency | - | M |
| 318408 | 2023 | 2024-09-03 | 485629 | 2023-003 | Significant Deficiency | Yes | I |
| 318408 | 2023 | 2024-09-03 | 485628 | 2023-002 | - | Yes | L |
| 305135 | 2022 | 2024-04-30 | 971843 | 2022-004 | Significant Deficiency | Yes | I |
| 305135 | 2022 | 2024-04-30 | 971842 | 2022-003 | Material Weakness | Yes | P |
| 305135 | 2022 | 2024-04-30 | 971841 | 2022-002 | Significant Deficiency | Yes | P |
| 305135 | 2022 | 2024-04-30 | 971840 | 2022-001 | Significant Deficiency | Yes | L |
| 305135 | 2022 | 2024-04-30 | 395401 | 2022-004 | Significant Deficiency | Yes | I |
| 305135 | 2022 | 2024-04-30 | 395400 | 2022-003 | Material Weakness | Yes | P |
| 305135 | 2022 | 2024-04-30 | 395399 | 2022-002 | Significant Deficiency | Yes | P |
| 305135 | 2022 | 2024-04-30 | 395398 | 2022-001 | Significant Deficiency | Yes | L |
| 298952 | 2021 | 2024-03-27 | 963069 | 2021-001 | Material Weakness | - | A |
| 298952 | 2021 | 2024-03-27 | 963068 | 2021-003 | Significant Deficiency | - | L |
| 298952 | 2021 | 2024-03-27 | 963067 | 2021-002 | Significant Deficiency | - | F |
| 298952 | 2021 | 2024-03-27 | 386627 | 2021-001 | Material Weakness | - | A |
| 298952 | 2021 | 2024-03-27 | 386626 | 2021-003 | Significant Deficiency | - | L |
| 298952 | 2021 | 2024-03-27 | 386625 | 2021-002 | Significant Deficiency | - | F |